Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Пути преодоления резистентности к эрлотинибу у больных немелкоклеточным раком легкого с мутацией EGFR (обзор литературы)
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассматриваются вопросы комбинированного применения химиотерапии и эрлотиниба для лечения больных немелкоклеточным раком легкого. Обсуждаются механизмы развивающейся резистентности к ингибиторам тирозинкиназы EGFR и возможные пути их преодоления. Представлены данные клинического исследования FASTACT-II, в котором использован последовательный прерывистый режим комбинированного применения ХТ и эрлотиниба в 1-й линии терапии НМРЛ. Этот новый подход доказал свою эффективность в азиатской популяции больных НМРЛ с мутацией EGFR.
Ключевые слова: немелкоклеточный рак легкого, мутации рецептора эпидермального фактора роста, эрлотиниб.
Ключевые слова: немелкоклеточный рак легкого, мутации рецептора эпидермального фактора роста, эрлотиниб.
________________________________________________
The aspects of chemotherapy and erlotinib combination to treatment of non-small-cell lung cancer (NSCLC) are examined in the article. Mechanisms of ITK resistance acquiring and potential ways to its overcoming are discussed. In the randomized clinical trial FASTACT-II the intercalated combination of chemotherapy and erlotinib was used in the 1st line treatment of NSCLC. The efficacy of new approach was proved to Asian patients with EGFR mutated NSCLC.
Key words: non-small-cell lung cancer, mutations of Epidermal Grouth Factor Receptor (EGFR), erlotinib.
Полный текст
Список литературы
1. Zhou C, Wu YL, Chen G et al. Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol 2010; 12 (8): 735–42.
2. Janne PA, Wang X, Socinski MA et al. Randomized Phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012; 30 (17): 2063–9.
3. Xu L, Kikuchi E, Xu C et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012; 72 (13): 3302–11.
4. Chen G, Noor A, Kronenberger P et al. Synergistic effect of afatinib with su11274 in non-small-cell lung cancer cells resistant to gefitinib or erlotinib. PLoS 2013; 8 (3): e59708.
5. Chen Z, Zhong W et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17: 7978–85.
6. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (25): 5892–9.
7. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J Clin Oncol 2004; 22 (5): 777–84.
8. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J Clin Oncol 2004; 22 (5): 785–94.
9. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25 (12): 1545–52.
10. Wu YL, Lee JS, Thongprasert S et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013; 14 (8): 777–86.
11. Goldberg SB, Oxnard GR, Digumarthy S, Sequist LV. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR TKI. ASCO Meeting 2012; Abstr. 30 (Suppl. 15): s7530.
12. Giovanetti E, Lemos C, Tekle C et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, en EGFR TKI, with multitargeted antifolate pemetrexed in NSCLC cells. Mol Pharmacol 2008; 73: 1290–300.
13. Wu SG, Yang CH, Yu CJ et al. Good response to pemetrexed in patients of lung adenocarcinoma with EGFR mutations. Lung Сancer 2011; 72: 333–43.
2. Janne PA, Wang X, Socinski MA et al. Randomized Phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012; 30 (17): 2063–9.
3. Xu L, Kikuchi E, Xu C et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012; 72 (13): 3302–11.
4. Chen G, Noor A, Kronenberger P et al. Synergistic effect of afatinib with su11274 in non-small-cell lung cancer cells resistant to gefitinib or erlotinib. PLoS 2013; 8 (3): e59708.
5. Chen Z, Zhong W et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012; 17: 7978–85.
6. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23 (25): 5892–9.
7. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J Clin Oncol 2004; 22 (5): 777–84.
8. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J Clin Oncol 2004; 22 (5): 785–94.
9. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25 (12): 1545–52.
10. Wu YL, Lee JS, Thongprasert S et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013; 14 (8): 777–86.
11. Goldberg SB, Oxnard GR, Digumarthy S, Sequist LV. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR TKI. ASCO Meeting 2012; Abstr. 30 (Suppl. 15): s7530.
12. Giovanetti E, Lemos C, Tekle C et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, en EGFR TKI, with multitargeted antifolate pemetrexed in NSCLC cells. Mol Pharmacol 2008; 73: 1290–300.
13. Wu SG, Yang CH, Yu CJ et al. Good response to pemetrexed in patients of lung adenocarcinoma with EGFR mutations. Lung Сancer 2011; 72: 333–43.
Авторы
С.В.Орлов
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова
Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова
________________________________________________
S.V.Orlov
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.